Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00073462 | Colorectum | FAP | regulation of mitotic cell cycle | 85/2622 | 457/18723 | 3.41e-03 | 2.48e-02 | 85 |
GO:0060428 | Colorectum | FAP | lung epithelium development | 12/2622 | 37/18723 | 3.43e-03 | 2.48e-02 | 12 |
GO:0030323 | Colorectum | FAP | respiratory tube development | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
GO:00611381 | Colorectum | FAP | morphogenesis of a branching epithelium | 39/2622 | 182/18723 | 3.98e-03 | 2.76e-02 | 39 |
GO:0030324 | Colorectum | FAP | lung development | 38/2622 | 177/18723 | 4.28e-03 | 2.93e-02 | 38 |
GO:00331431 | Colorectum | FAP | regulation of intracellular steroid hormone receptor signaling pathway | 19/2622 | 74/18723 | 5.52e-03 | 3.58e-02 | 19 |
GO:00305201 | Colorectum | FAP | intracellular estrogen receptor signaling pathway | 15/2622 | 54/18723 | 5.99e-03 | 3.77e-02 | 15 |
GO:00510901 | Colorectum | FAP | regulation of DNA-binding transcription factor activity | 80/2622 | 440/18723 | 7.90e-03 | 4.67e-02 | 80 |
GO:00459311 | Colorectum | FAP | positive regulation of mitotic cell cycle | 27/2622 | 121/18723 | 8.64e-03 | 4.98e-02 | 27 |
GO:00020645 | Colorectum | CRC | epithelial cell development | 55/2078 | 220/18723 | 4.63e-09 | 1.16e-06 | 55 |
GO:00487325 | Colorectum | CRC | gland development | 88/2078 | 436/18723 | 1.62e-08 | 2.79e-06 | 88 |
GO:00713834 | Colorectum | CRC | cellular response to steroid hormone stimulus | 51/2078 | 204/18723 | 1.67e-08 | 2.79e-06 | 51 |
GO:00305224 | Colorectum | CRC | intracellular receptor signaling pathway | 61/2078 | 265/18723 | 2.00e-08 | 3.23e-06 | 61 |
GO:00434015 | Colorectum | CRC | steroid hormone mediated signaling pathway | 37/2078 | 136/18723 | 1.52e-07 | 1.66e-05 | 37 |
GO:00097555 | Colorectum | CRC | hormone-mediated signaling pathway | 46/2078 | 190/18723 | 2.28e-07 | 2.27e-05 | 46 |
GO:00305184 | Colorectum | CRC | intracellular steroid hormone receptor signaling pathway | 32/2078 | 116/18723 | 7.37e-07 | 4.79e-05 | 32 |
GO:00485455 | Colorectum | CRC | response to steroid hormone | 67/2078 | 339/18723 | 1.77e-06 | 8.92e-05 | 67 |
GO:00457855 | Colorectum | CRC | positive regulation of cell adhesion | 81/2078 | 437/18723 | 2.28e-06 | 1.10e-04 | 81 |
GO:00063254 | Colorectum | CRC | chromatin organization | 74/2078 | 409/18723 | 1.48e-05 | 4.61e-04 | 74 |
GO:00226124 | Colorectum | CRC | gland morphogenesis | 29/2078 | 118/18723 | 2.74e-05 | 7.49e-04 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FOXA1 | SNV | Missense_Mutation | novel | c.637C>T | p.Arg213Cys | p.R213C | P55317 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
FOXA1 | SNV | Missense_Mutation | novel | c.22G>A | p.Glu8Lys | p.E8K | P55317 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
FOXA1 | SNV | Missense_Mutation | | c.1350N>G | p.Ile450Met | p.I450M | P55317 | protein_coding | tolerated(0.35) | benign(0.07) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
FOXA1 | SNV | Missense_Mutation | | c.739N>T | p.His247Tyr | p.H247Y | P55317 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
FOXA1 | SNV | Missense_Mutation | | c.749N>T | p.Ser250Phe | p.S250F | P55317 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
FOXA1 | SNV | Missense_Mutation | | c.676N>A | p.Asp226Asn | p.D226N | P55317 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FOXA1 | SNV | Missense_Mutation | novel | c.764N>T | p.Glu255Val | p.E255V | P55317 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FOXA1 | SNV | Missense_Mutation | | c.526A>G | p.Ile176Val | p.I176V | P55317 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FOXA1 | SNV | Missense_Mutation | novel | c.677A>G | p.Asp226Gly | p.D226G | P55317 | protein_coding | deleterious(0) | possibly_damaging(0.762) | TCGA-AC-A4ZE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FOXA1 | SNV | Missense_Mutation | novel | c.1213N>T | p.Leu405Phe | p.L405F | P55317 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |